404 related articles for article (PubMed ID: 29057791)
1. Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review.
Cornelison R; Llaneza DC; Landen CN
Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29057791
[TBL] [Abstract][Full Text] [Related]
2. PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN; Eskander RN
Recent Pat Anticancer Drug Discov; 2018; 13(2):145-158. PubMed ID: 29205122
[TBL] [Abstract][Full Text] [Related]
3. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
4. FOXM1 confers to epithelial-mesenchymal transition, stemness and chemoresistance in epithelial ovarian carcinoma cells.
Chiu WT; Huang YF; Tsai HY; Chen CC; Chang CH; Huang SC; Hsu KF; Chou CY
Oncotarget; 2015 Feb; 6(4):2349-65. PubMed ID: 25537512
[TBL] [Abstract][Full Text] [Related]
5. Poly(ADP-ribose) polymerase (PARP) inhibitors and ovarian cancer.
Liu CH; Chang Y; Wang PH
Taiwan J Obstet Gynecol; 2017 Oct; 56(5):713-714. PubMed ID: 29037569
[No Abstract] [Full Text] [Related]
6. Hedgehog signaling regulates drug sensitivity by targeting ABC transporters ABCB1 and ABCG2 in epithelial ovarian cancer.
Chen Y; Bieber MM; Teng NN
Mol Carcinog; 2014 Aug; 53(8):625-34. PubMed ID: 23423781
[TBL] [Abstract][Full Text] [Related]
7. Targeting pathways contributing to epithelial-mesenchymal transition (EMT) in epithelial ovarian cancer.
Huang RY; Chung VY; Thiery JP
Curr Drug Targets; 2012 Dec; 13(13):1649-53. PubMed ID: 23061545
[TBL] [Abstract][Full Text] [Related]
8. Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.
Della Pepa C; Tonini G; Santini D; Losito S; Pisano C; Di Napoli M; Cecere SC; Gargiulo P; Pignata S
Cancer Treat Rev; 2015 Feb; 41(2):136-43. PubMed ID: 25573350
[TBL] [Abstract][Full Text] [Related]
9. NANOG regulates epithelial-mesenchymal transition and chemoresistance in ovarian cancer.
Qin S; Li Y; Cao X; Du J; Huang X
Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 27884977
[TBL] [Abstract][Full Text] [Related]
10. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer.
Pan JX; Qu F; Wang FF; Xu J; Mu LS; Ye LY; Li JJ
Arch Gynecol Obstet; 2017 Dec; 296(6):1145-1152. PubMed ID: 28975405
[TBL] [Abstract][Full Text] [Related]
11. Veliparib Monotherapy to Patients With BRCA Germ Line Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer: A Phase I/II Study.
Steffensen KD; Adimi P; Jakobsen A
Int J Gynecol Cancer; 2017 Nov; 27(9):1842-1849. PubMed ID: 28763368
[TBL] [Abstract][Full Text] [Related]
12. Development of Olaparib for BRCA-Deficient Recurrent Epithelial Ovarian Cancer.
Tewari KS; Eskander RN; Monk BJ
Clin Cancer Res; 2015 Sep; 21(17):3829-35. PubMed ID: 26169965
[TBL] [Abstract][Full Text] [Related]
13. PARP inhibitors and epithelial ovarian cancer: an approach to targeted chemotherapy and personalised medicine.
Mukhopadhyay A; Curtin N; Plummer R; Edmondson RJ
BJOG; 2011 Mar; 118(4):429-32. PubMed ID: 21244617
[TBL] [Abstract][Full Text] [Related]
14. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance.
Oda K; Tanikawa M; Sone K; Mori-Uchino M; Osuga Y; Fujii T
Int J Clin Oncol; 2017 Aug; 22(4):611-618. PubMed ID: 28508305
[TBL] [Abstract][Full Text] [Related]
16. The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer.
Yan S; Frank D; Son J; Hannan KM; Hannan RD; Chan KT; Pearson RB; Sanij E
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28117679
[TBL] [Abstract][Full Text] [Related]
17. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer.
Zhao H; Liu S; Wang G; Wu X; Ding Y; Guo G; Jiang J; Cui S
Oncol Rep; 2015 Feb; 33(2):591-8. PubMed ID: 25482209
[TBL] [Abstract][Full Text] [Related]
18. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
19. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
[TBL] [Abstract][Full Text] [Related]
20. Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.
Lambrechts S; Smeets D; Moisse M; Braicu EI; Vanderstichele A; Zhao H; Van Nieuwenhuysen E; Berns E; Sehouli J; Zeillinger R; Darb-Esfahani S; Cacsire Castillo-Tong D; Lambrechts D; Vergote I
Eur J Cancer; 2016 Jan; 53():51-64. PubMed ID: 26693899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]